NexImmune, Inc. - Common Stock (OQ:NEXI)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Feb 06, 2024 04:42 pm ET

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today...

Feb 02, 2024 02:00 pm ET

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 03, 2024 08:31 am ET

Thinking about buying stock in Dyne Therapeutics, Applied Therapeutics, ON Semiconductor, Mereo BioPharma, or Neximmune?

NEW YORK, Jan. 3, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DYN, APLT, ON, MREO, and NEXI.

Dec 04, 2023 08:31 am ET

Thinking about buying stock in Johnson & Johnson, Fortress Biotech, MicroStrategy, Neximmune, or ShiftPixy?

NEW YORK, Dec. 4, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JNJ, FBIO, MSTR, NEXI, and PIXY.

Dec 01, 2023 08:31 am ET

Thinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc?

NEW YORK, Dec. 1, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEXI, PIXY, AMPE, SEEL, and NIO.

Oct 24, 2023 08:00 am ET

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes...

Oct 19, 2023 08:00 am ET

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting

Oct 18, 2023 11:30 am ET

NexImmune Announces 1-for-25 Reverse Stock Split

NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and...

Aug 31, 2023 04:45 pm ET

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy

Aug 10, 2023 04:01 pm ET

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious...

Jun 05, 2023 08:01 am ET

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no grade > - NexImmune, Inc. (Nasdaq: NEXI), a biotechnology...

May 22, 2023 04:01 pm ET

NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting

May 15, 2023 04:01 pm ET

NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 26, 2023 04:01 pm ET

NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting

Mar 28, 2023 04:01 pm ET

NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Feb 16, 2023 09:58 am ET

Thinking about buying stock in Neximmune, Inozyme Pharma, Shopify, AMC Entertainment, or ContextLogic?

NEW YORK, Feb. 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEXI, INZY, SHOP, AMC, and WISH.

Feb 16, 2023 07:00 am ET

NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

specific AIM ACT CD8 T cells are superior to polyclonal peripheral blood CD4 T cells, naïve CD8 T cells, and bulk CD8 T cells as effectors of BiTE-mediated killing in vivo GAITHERSBURG, Md., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NexImmune,...

Jan 18, 2023 04:01 pm ET

NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform to Treat Viral Diseases

Nov 14, 2022 04:01 pm ET

NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update

Oct 06, 2022 07:00 am ET

NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a...

Sep 09, 2022 04:01 pm ET

NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 08, 2022 09:36 am ET

Thinking about buying stock in Neximmune, ShiftPixy, IN8BIO, Relay Therapeutics, or Reata Pharmaceuticals?

NEW YORK, Sept. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEXI, PIXY, INAB, RLAY, and RETA.

Sep 08, 2022 07:00 am ET

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments

Aug 15, 2022 04:05 pm ET

NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers

Jul 15, 2022 09:36 am ET

Thinking about buying stock in Allogene Therapeutics, Neximmune, Vertical Aerospace, Sonim Technologies, or DigitalBridge?

NEW YORK, July 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALLO, NEXI, EVTL, SONM, and DBRG.

Jul 14, 2022 04:09 pm ET

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

related cancers GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by...

May 12, 2022 04:01 pm ET

NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates

May 10, 2022 04:01 pm ET

NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

NexImmune, Inc. (Nasdaq: NEXI), Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The $600,000...

May 10, 2022 07:30 am ET

NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors

Apr 26, 2022 07:30 am ET

NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center

Apr 14, 2022 04:01 pm ET

NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer

Mar 29, 2022 08:31 am ET

Thinking about buying stock in Hycroft Mining, Nielsen, Neximmune, 4D pharma, or Ginkgo Bioworks?

NEW YORK, March 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HYMC, NLSN, NEXI, LBPS, and DNA.

Mar 17, 2022 07:30 am ET

NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology. Combining Zephyr’s proprietary artificial...

Mar 14, 2022 07:30 am ET

NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

Mar 10, 2022 04:26 pm ET

NexImmune to Present at the Barclays 2022 Global Healthcare Conference

Mar 09, 2022 04:33 pm ET

NexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

Feb 17, 2022 04:15 pm ET

NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors

Feb 01, 2022 07:00 am ET

NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets

Jan 18, 2022 04:01 pm ET

NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”

Jan 05, 2022 04:01 pm ET

NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board

Dec 12, 2021 03:40 pm ET

NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma

Nov 12, 2021 07:30 am ET

NexImmune Reports Third Quarter 2021 Financial Results and Provides Business Updates

Nov 08, 2021 04:01 pm ET

NexImmune to Announce Third Quarter 2021 Financial Results and Provide Corporate Update on November 12, 2021

Nov 03, 2021 08:00 am ET

NexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting

Sep 27, 2021 04:01 pm ET

NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference

Sep 10, 2021 09:10 am ET

NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Aug 09, 2021 04:05 pm ET

NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates

Aug 09, 2021 04:01 pm ET

NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes

Jul 27, 2021 04:01 pm ET

NexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

Jul 14, 2021 04:01 pm ET

NexImmune Strengthens Management Team with Key Appointments

Jun 16, 2021 04:29 pm ET

NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference

May 27, 2021 08:00 am ET

NexImmune Announces Formation of Scientific Advisory Board

May 19, 2021 04:21 pm ET

NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual Meeting

May 17, 2021 04:01 pm ET

NexImmune Reports First Quarter 2021 Financial Results and Recent Updates

Apr 21, 2021 07:30 am ET

NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs

Mar 31, 2021 04:54 pm ET

NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates

Mar 02, 2021 04:01 pm ET

NexImmune to Present at the 2021 Barclays Global Healthcare Conference

Feb 24, 2021 07:30 am ET

Rapha Capital Management Announces Successful Initial Public Offering of Portfolio Company NexImmune Inc.

MIAMI, Feb. 24, 2021 /PRNewswire/ -- Rapha Capital Management, LLC (https://raphacap.com), an investment management firm located in Miami, Florida, is pleased to announce that on February 17, 2021, its portfolio company, NexImmune, Inc. ("NexImmune"), closed an upsized initial public offering raising gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $126.5 million. The gross proceeds included the exercise in full by the underwriters of their option to purchase additional shares. NexImmune's shares are traded on the Nasdaq Global M

Feb 23, 2021 07:00 am ET

Barer & Son Capital and Hibiscus Capital Management Announce Successful Initial Public Offering of Portfolio Company NexImmune

ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ -- Barer & Son Capital, a life science venture capital fund managed by Hibiscus Capital Management, is pleased to announce that on February 17, 2021, its portfolio company, NexImmune, Inc. ("NexImmune"), closed an upsized initial public offering raising gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $126.5 million. The gross proceeds included the exercise in full by the underwriters of their option to purchase additional shares. NexImmune's shares are traded on the Nasdaq Global Ma

Feb 17, 2021 06:34 pm ET

NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response, today announced the closing of...

Feb 11, 2021 10:03 pm ET

NexImmune Announces Pricing of Upsized Initial Public Offering

NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced...

Ad blocking detected

NexImmune, Inc. - Common Stock (OQ:NEXI)

Business Focus: N/A